A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Sitagliptin 100 mg/simvastatin 40 mg FDC
Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Has type 2 diabetes mellitus
- Male, or female who is not of reproductive potential or if of reproductive potential agrees to abstain or use (or have their partner use) two acceptable methods of birth control during the study and for 14 days after the last dose of study drug
- Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to study participation
- Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to study participation
Exclusion Criteria:
- History of type 1 diabetes mellitus or a history of ketoacidosis
- History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of consciousness over the past 3 months
- On a thiazolidinedione (TZD) within the past 12 weeks
- Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to study participation
- Is on or likely to require treatment with a prohibited medication (itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine, niacin)
- Intends to consume >1.2 liters of grapefruit juice per day during the study
- Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)
- Is on a weight loss program and not in the maintenance phase or has started a weight loss medication or has undergone bariatric surgery within 12 months prior to study participation
- Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
- History of myopathy or rhabdomyolysis with any statin
- History of myocardial infarction, unstable or stable angina, angioplasty, bypass surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm, transient ischemic attacks, stroke of carotid origin or >50% obstruction of a carotid artery
- Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class III or IV cardiac status
- History of active liver disease (other than non-alcoholic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
- Chronic progressive neuromuscular disorder
- Human immunodeficiency virus (HIV)
- Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
- Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks
- History of malignancy <=5 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer
- Positive urine pregnancy test
- Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
- User of recreational or illicit drugs or has had a recent history of drug abuse
- Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sitagliptin 100 mg/simvastatin 40 mg FDC
Arm Description
Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
Outcomes
Primary Outcome Measures
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.
Percentage of Participants Who Experienced at Least One Adverse Event
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.
Secondary Outcome Measures
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Change From Baseline in Total Cholesterol (TC)
Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)
Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Change From Baseline in Triglycerides (TG)
Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01702298
Brief Title
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
Official Title
An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
December 7, 2012 (Actual)
Primary Completion Date
May 29, 2013 (Actual)
Study Completion Date
May 29, 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin 100 mg/simvastatin 40 mg FDC
Arm Type
Experimental
Arm Description
Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin 100 mg/simvastatin 40 mg FDC
Other Intervention Name(s)
MK-0431D
Intervention Description
Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
Intervention Description
Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
Primary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose (FPG)
Description
Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.
Time Frame
Baseline and Week 6
Title
Percentage of Participants Who Experienced at Least One Adverse Event
Description
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
Time Frame
Up to 8 weeks (including 14 days after final dose of study drug)
Title
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Description
Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.
Time Frame
Up to 6 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Description
Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Time Frame
Baseline and Week 6
Title
Change From Baseline in Total Cholesterol (TC)
Description
Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Time Frame
Baseline and Week 6
Title
Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)
Description
Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Time Frame
Baseline and Week 6
Title
Change From Baseline in Triglycerides (TG)
Description
Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).
Time Frame
Baseline and Week 6
Title
Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Description
Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
Time Frame
Baseline and Week 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has type 2 diabetes mellitus
Male, or female who is not of reproductive potential or if of reproductive potential agrees to abstain or use (or have their partner use) two acceptable methods of birth control during the study and for 14 days after the last dose of study drug
Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to study participation
Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to study participation
Exclusion Criteria:
History of type 1 diabetes mellitus or a history of ketoacidosis
History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of consciousness over the past 3 months
On a thiazolidinedione (TZD) within the past 12 weeks
Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to study participation
Is on or likely to require treatment with a prohibited medication (itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine, niacin)
Intends to consume >1.2 liters of grapefruit juice per day during the study
Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)
Is on a weight loss program and not in the maintenance phase or has started a weight loss medication or has undergone bariatric surgery within 12 months prior to study participation
Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
History of myopathy or rhabdomyolysis with any statin
History of myocardial infarction, unstable or stable angina, angioplasty, bypass surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm, transient ischemic attacks, stroke of carotid origin or >50% obstruction of a carotid artery
Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class III or IV cardiac status
History of active liver disease (other than non-alcoholic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
Chronic progressive neuromuscular disorder
Human immunodeficiency virus (HIV)
Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks
History of malignancy <=5 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer
Positive urine pregnancy test
Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
User of recreational or illicit drugs or has had a recent history of drug abuse
Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Available IPD and Supporting Information:
Available IPD/Information Type
CSR Synopsis
Available IPD/Information URL
http://www.merck.com/clinical-trials/study.html?id=0431D-312&kw=0431D-312&tab=access
Learn more about this trial
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
We'll reach out to this number within 24 hrs